Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | PRCP | P42785 | 2/20 | 0.42 |
| ▸ | GLI1 | P08151 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969952 | 1.00 | NOS2 (0.50) | NOS2NOS3NOS1PRCPGLI1 | |
| SCHEMBL7432758 | 0.82 | NOS2 (0.48) | NOS2NOS3NOS1PRCPGLI1 | |
| SCHEMBL4733722 | 0.82 | PRCP (0.44) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL4733724 | 0.82 | PRCP (0.44) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL4733728 | 0.82 | PRCP (0.44) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL4012939 | 0.80 | PRCP (0.46) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL29471063 | 0.80 | PRCP (0.42) | NOS2NOS3NOS1PRCPGLI1 | |
| SCHEMBL2496026 | 0.80 | PRCP (0.46) | NOS2NOS3NOS1PRCPGLI1 | |
| SCHEMBL4685341 | 0.80 | PRCP (0.46) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL8062198 | 0.79 | NOS2 (0.46) | NOS2NOS3NOS1PRCPGLI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-12-27 | — | — | US | claimed |
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-10-26 | — | — | US | claimed |
| EP-1450841-A4 | TRI-, TETRA-, AND PENTA-PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2007-01-24 | — | — | EP | claimed |
| US-7037897-B2 | TRI-, TETRA-, and penta-peptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | claimed |
| EP-1450841-A2 | TRI-, TETRA-, AND PENTA-PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-09-01 | — | — | EP | claimed |
| US-20030109456-A1 | TRI-, TETRA-, and penta-peptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | claimed |
| WO-2003037912-A2 | TRI-, TETRA-, AND PENTA-PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| US-4318905-A | Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues | SYNTEX (U.S.A.) INC. (US) | 1982-03-09 | — | — | US | claimed |
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-12-27 | — | — | US | disclosed |
| US-10081668-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2018-09-25 | — | — | US | disclosed |
| WO-2017189715-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-10-26 | — | — | US | disclosed |
| EP-2177530-B1 | Octapeptide having antiangiogenic activity | ABBOTT LAB (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-0042753-B1 | NONAPEPTIDE AND DECAPEPTIDE AGONISTS OF LUTEINIZING HORMONE RELEASING HORMONE CONTAINING HETEROCYCLIC AMINO ACID RESIDUES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOUNDS CONTAINING THEM, AND THEIR PHARMACEUTICAL USE | SYNTEX (U.S.A.) INC. (US) | 1984-03-21 | — | — | EP | disclosed |
| US-4338305-A | LUTEINIZING HORMONE RELEASING HORMONE; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-07-06 | — | — | US | disclosed |
| US-4318905-A | Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues | SYNTEX (U.S.A.) INC. (US) | 1982-03-09 | — | — | US | disclosed |
| EP-0042753-A1 | Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues, methods for their preparation, pharmaceutical compounds containing them, and their pharmaceutical use | SYNTEX (U.S.A.) INC. (US) | 1981-12-30 | — | — | EP | disclosed |
| EP-0021234-A1 | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4234571-A | CONTRACEPTIVES, ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | VEGFA, LITAF, HDGF | NOS2 910/4885NOS3 628/4885NOS1 1178/4885 |
| US-10081668-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | NOS2 933/4885NOS3 649/4885NOS1 1186/4885 |
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | NOS2 933/4885NOS3 649/4885NOS1 1186/4885 |
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | VEGFA, LITAF, HDGF | NOS2 910/4885NOS3 628/4885NOS1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.